BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2434790)

  • 1. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.
    Fasanella d'Amore T; Bussien JP; Nussberger J; Waeber B; Turini GA; Brunner HR; Kler L; Francis RJ
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):26-31. PubMed ID: 2434790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers.
    Nussberger J; Fasanella d'Amore T; Porchet M; Waeber B; Brunner DB; Brunner HR; Kler L; Brown AN; Francis RJ
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):39-44. PubMed ID: 2434792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGS 13945: a new orally active angiotensin-converting enzyme inhibitor in normal volunteers.
    Jacot des Combes B; Turini GA; Brunner HR; Porchet M; Chen DS; Sen S
    J Cardiovasc Pharmacol; 1983; 5(4):511-6. PubMed ID: 6193344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.
    Francis RJ; Brown AN; Kler L; Fasanella d'Amore T; Nussberger J; Waeber B; Brunner HR
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):32-8. PubMed ID: 2434791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.
    Sánchez RA; Traballi CA; Barclay CA; Gilbert HB; Muscará M; Giannone C; Moledo LI
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):230-4. PubMed ID: 2452319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen.
    Fernandez PG; Bolli P; Lee C
    Can J Cardiol; 1990 Mar; 6(2):53-8. PubMed ID: 2138051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with perindopril in normal volunteers.
    Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
    Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():35-41. PubMed ID: 2549899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of studies on the clinical pharmacodynamics of cilazapril.
    Belz GG; Breithaupt K; Erb K
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S14-9. PubMed ID: 7898090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
    Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
    J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.
    Burnier M; Mooser V; Nussberger J; Waeber B; Brunner HR
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):189S-197S. PubMed ID: 2527532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with perindopril in normal volunteers.
    Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
    Clin Exp Hypertens A; 1989; 11 Suppl 2():507-19. PubMed ID: 2605800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.
    Belz GG; Essig J; Kleinbloesem CH; Hoogkamer JF; Wiegand UW; Wellstein A
    Br J Clin Pharmacol; 1988 Nov; 26(5):547-56. PubMed ID: 2974715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of antihypertensive medications on the physiological response to maximal exercise testing.
    Derman WE; Sims R; Noakes TD
    J Cardiovasc Pharmacol; 1992; 19 Suppl 5():S122-7. PubMed ID: 1381788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilazapril inhibits vascular responses to baroreflex-stimulated sympathetic neural activity in hypertensive patients.
    Fernandez PG; Bolli P; Lee C; Vasdev S
    Can J Cardiol; 1990; 6(1):9-14. PubMed ID: 2138049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ro 42-5892 is a potent orally active renin inhibitor in primates.
    Fischli W; Clozel JP; el Amrani K; Wostl W; Neidhart W; Stadler H; Branca Q
    Hypertension; 1991 Jul; 18(1):22-31. PubMed ID: 1830563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin-induced hypertension in marmosets: a new model of hypertension sensitive to angiotensin-converting enzyme inhibition.
    Clozel JP; Fischli W
    J Cardiovasc Pharmacol; 1989 Jul; 14(1):77-81. PubMed ID: 2475720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat].
    Ingert C; Grima M; Michel B; Barthelmebs M; Imbs JL
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1135-41. PubMed ID: 9404423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin modulation of sympathetic reflex function in essential hypertension and in the elderly.
    Ajayi AA; Reid JL
    Int J Clin Pharmacol Res; 1988; 8(5):327-33. PubMed ID: 2852643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of eight-day converting enzyme inhibition on ambulatory blood pressure recordings in normotensive volunteers.
    Bidiville J; Porchet M; Bussien JP; Nussberger J; Waeber B; Brunner HR
    Arch Int Pharmacodyn Ther; 1987 Jul; 288(1):109-19. PubMed ID: 2959228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function.
    Shionoiri H; Gotoh E; Takagi N; Takeda K; Yabana M; Kaneko Y
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):242-9. PubMed ID: 2452321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.